A phase II study evaluating the feasibility of a 5-week cycle of S-1 plus irinotecan (IRIS) in patients with advanced and recurrent colorectal cancer

@article{Hata2013API,
  title={A phase II study evaluating the feasibility of a 5-week cycle of S-1 plus irinotecan (IRIS) in patients with advanced and recurrent colorectal cancer},
  author={Taishi Hata and Mutsumi Fukunaga and Kohei Murata and Yoshio Uemura and Takayuki Fukuzaki and Hirofumi Ota and Masayuki Ohue and Tadashi Ohnishi and Nobuo Tanaka and Ichiro Takemasa and Tsunekazu Mizushima and Masataka Ikeda and Hirofumi Yamamoto and Mitsugu Sekimoto and Riichiro Nezu and Yuichiro Doki and Masaki Mori},
  journal={Cancer Chemotherapy and Pharmacology},
  year={2013},
  volume={71},
  pages={1657-1663}
}
A number of clinical trials, including the FIRIS study, have shown that S-1 plus irinotecan (IRIS) is safe and effective in patients with colorectal cancer. Several different treatment protocols for IRIS are commonly used in Japan, besides the one used in the FIRIS study. This study was designed to evaluate the feasibility of a 5-week cycle of IRIS. Between… CONTINUE READING